Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:ENTX

Entera Bio Q2 2024 Earnings Report

Entera Bio logo
$1.23 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$1.23 0.00 (-0.41%)
As of 06/12/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Entera Bio EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.06
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Entera Bio Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Entera Bio Announcement Details

Quarter
Q2 2024
Date
8/9/2024
Time
After Market Closes
Conference Call Date
Friday, August 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Entera Bio's Q2 2026 earnings is estimated for Friday, August 14, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Entera Bio's Q2 2024 Press ReleasePress Release
(8-K)
Entera Bio's Q2 2024 Quarterly reportQuarterly report
(10-Q)

Entera Bio Earnings Headlines

Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)
June 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ARWR-Q/pressreleases/2259984/entera-bio-is-building-the-future-of-peptides-beyond-the-needle-nasdaq-entx/
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting ...
May 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/entera-s-eb613-first-in-class-oral-pth-1-34-anabolic-for-osteoporosis---single-tablet-data-selected-for-late-breaking-oral-presentation-at-endo-2026-annual-meeting-additional-oral-peptide-1036202739
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillion in stored capital will be looking for a home when it does. But the real opportunity isn't the IPO itself. Jovine has identified a small-cap supplier trading near $4 that sits directly in the path of xAI's Colossus infrastructure buildout - and a specific trigger in the S-1 could reprice it overnight.tc pixel
June 15 at 1:00 AM  |  Behind the Markets (Ad)
Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302886/0/en/entera-s-eb613-first-in-class-oral-pth-1-34-anabolic-for-osteoporosis-single-tablet-data-selected-for-late-breaking-oral-presentation-at-endo-2026-annual-meeting-additional-oral-pe.html
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
May 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/08/3291323/0/en/entera-announces-first-quarter-2026-financial-results-and-updates-across-its-oral-peptide-programs.html
Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript
April 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4892087-entera-bio-ltd-entx-discusses-osteoporosis-treatment-landscape-and-clinical-potential-of
See More Entera Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Entera Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entera Bio and other key companies, straight to your email.

About Entera Bio

Entera Bio (NASDAQ:ENTX), Inc. is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis. EB613 entered Phase 1 clinical trials to assess safety, tolerability and pharmacokinetics in healthy volunteers. In parallel, Entera Bio is advancing EB612, an oral tumor necrosis factor (TNF) antagonist, toward early‐stage clinical development for inflammatory diseases such as rheumatoid arthritis and Crohn’s disease.

Since its founding in 2010, Entera Bio has established operations in Newton, Massachusetts, and research facilities in Israel, positioning the company at the intersection of North American and international biopharmaceutical innovation. Its leadership team combines expertise in peptide chemistry, clinical development, regulatory affairs and commercial strategy. Entera Bio plans to collaborate with established pharmaceutical partners to support late‐stage clinical programs and the global commercialization of its oral peptide product candidates.

View Entera Bio Profile
Earnings Tools